Poor
Not Aligned
Patient Risk:
High
Summary
Multiple extracted claims are absent or contradicted by the provided label excerpts (especially pregnancy/breastfeeding being described as 'not recommended' and multiple specific interaction/contraindication assertions not present). Only the triglyceride-lowering indication and general increased bleeding risk with concomitant antithrombotics are supported (with some overgeneralization).
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription medication used to lower triglyceride levels in adults with severe hypertriglyceridemia.
Indications and Usage: adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia (Section 1).
Vascepa may increase the risk of bleeding when taken with blood thinners such as warfarin or aspirin.
Warnings/Precautions 5.3: incidence of bleeding greater in patients receiving concomitant antithrombotic medications such as aspirin or warfarin.
Monitoring bleeding risk is recommended, especially if taking blood thinners.
Drug Interactions 7.1: Monitor patients receiving VASCEPA and concomitant anticoagulants and/or antiplatelet agents for bleeding.
Unsupported Statements
Vascepa can increase the risk of muscle damage when taken with statins such as atorvastatin or simvastatin.
No statin/muscle damage interaction information is present in the provided label excerpts.
Vascepa may increase the risk of bleeding when taken with anti-inflammatory medications such as ibuprofen or naproxen.
Provided label excerpts do not mention ibuprofen or naproxen; bleeding guidance is limited to anticoagulants/antiplatelet/antithrombotic agents.
Vascepa may interact with rifampin, which can decrease its effectiveness.
No rifampin interaction information is present in the provided label excerpts.
Taking high doses of omega-3 fatty acids with Vascepa may increase the risk of bleeding.
Label excerpt 7.1 discusses prolongation of bleeding time in some published studies with omega-3 fatty acids and advises monitoring with concomitant anticoagulants/antiplatelet agents; the provided excerpt does not support 'high doses of omega-3 fatty acids with Vascepa' as a standalone risk statement.
Ginkgo biloba may increase the risk of bleeding when taken with Vascepa.
No ginkgo biloba interaction information is present in the provided label excerpts.
High doses of vitamin E may interact with Vascepa, increasing the risk of bleeding.
No vitamin E interaction information is present in the provided label excerpts.
Taking fish oil supplements with Vascepa may increase the risk of bleeding.
Provided label excerpts do not specifically state fish oil supplements as a separate risk statement.
Consuming high-fat foods with Vascepa may decrease its absorption.
No food absorption information (e.g., high-fat foods) is present in the provided label excerpts.
Grapefruit juice may interact with Vascepa, increasing the risk of bleeding.
No grapefruit juice interaction information is present in the provided label excerpts.
Vascepa is contraindicated in patients with bleeding disorders such as hemophilia.
Provided contraindications excerpt only lists hypersensitivity to VASCEPA or components; no bleeding-disorder contraindication is present.
Vascepa is contraindicated in patients with severe liver disease.
Provided contraindications excerpt does not mention severe liver disease.
Vascepa is not recommended for pregnant women.
Provided pregnancy section states available data are insufficient to identify a drug-associated risk; it does not state 'not recommended.'
Vascepa is not recommended for breastfeeding women.
Provided lactation section discusses presence of omega-3 in milk and consideration of benefits/risks; it does not state 'not recommended.'
Informing a doctor about all medications, supplements, and foods is recommended to ensure safe use of Vascepa.
The provided patient counseling excerpt advises reading FDA-approved labeling and includes specific risk counseling, but does not include advice to inform a doctor about 'all medications, supplements, and foods.'
Regular blood tests may be necessary to monitor triglyceride levels and bleeding risk.
No label excerpt provided states regular blood tests are necessary to monitor triglyceride levels or bleeding risk; 7.1 supports bleeding monitoring in patients receiving concomitant anticoagulants/antiplatelet agents.
Contradictions
High
AI Statement
Vascepa is not recommended for pregnant women.
Label Reference
8.1 Pregnancy: available data are insufficient to identify a drug-associated risk; no 'not recommended' statement provided in the excerpt.
High
AI Statement
Vascepa is not recommended for breastfeeding women.
Label Reference
8.2 Lactation: includes risk summary and benefit consideration; no 'not recommended' statement provided in the excerpt.
Low
AI Statement
Vascepa may increase the risk of bleeding when taken with blood thinners such as warfarin or aspirin.
Label Reference
5.3 Bleeding indicates greater incidence with concomitant antithrombotic medications; phrasing implies a general 'may increase risk' across blood thinners beyond the specific concomitant antithrombotic context described.
Important Omissions
Indications context not fully captured: Vascepa also has cardiovascular risk reduction indication as adjunct to maximally tolerated statin therapy in specific adult populations; the claim set focuses only on TG reduction in severe hypertriglyceridemia.
Importance:
Low
No mention of counseling points supported by label (e.g., atrial fibrillation/atrial flutter risk, swallow whole capsules, missed dose guidance).
Importance:
Low
Safety Assessment
Potential Patient Risk:
High
Several statements introduce specific contraindications and interactions not supported by the provided label excerpts and misstate pregnancy/lactation guidance as 'not recommended,' which could misinform risk/eligibility decisions relative to the label text provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Numerous extracted claims are unsupported/absent in the provided FDA label excerpts, and pregnancy/breastfeeding statements are phrased contrary to the provided label risk summaries.
Suggested Improvement
Restrict interaction/contraindication claims to those explicitly present in the provided label sections (e.g., bleeding risk with concomitant anticoagulants/antiplatelet/antithrombotic agents per 5.3 and 7.1) and revise pregnancy/lactation statements to match the label excerpts (insufficient data/risk summary/benefit consideration rather than 'not recommended').